STOCKHOLM, SWEDEN September 4, 2026. KDventures AB (Nasdaq Stockholm: KDV) announces that its portfolio company Modus Therapeutics has carried out a directed issue of MSEK 7.6. The net proceeds will finance the company’s development plan for the drug candidate sevuparin during 2027.
Investors in the directed issue are Tellus Equity AB, Selandia Alpha Invest A/S, and certain existing minor shareholders. The directed issue of 20,000,000 shares was subscribed at a price of SEK 0.38 per share, resulting in net proceeds of MSEK 7.6 before transaction costs.
The net proceeds will be used to manufacture pharmaceutical product for future activities, for example, in the research cooperation within severe malaria, as well as business development activities in case the ongoing phase 2a study in chronic kidney disease with anemia generates positive data.
“Modus Therapeutics is approaching a critical value-driving inflection point, with proof-of-concept data expected around the turn of the year. The rights issue is a well-considered and necessary step to enable the company to act decisively on the opportunities that may arise, both in its drug development work and in business development. We also welcome new larger shareholders who share our view of the company’s potential and long-term value creation,” says Viktor Drvota, CEO of KDventures.
KDventures' ownership in Modus Therapeutics after the transaction amounts to 51 percent.